What happened, in summary

A 65-year-old woman was under follow-up after treatment for a separate HER2-positive left-breast cancer. At the 12-month review, she was diagnosed with in situ lobular carcinoma of the right breast, a distinct second primary rather than recurrence of the earlier invasive ductal cancer. Treatment for the right-sided lesion consisted of right mastectomy. Her later genetic evaluation found no known pathogenic BRCA1/2 mutation but identified a FANCA P1222L variant of uncertain significance. Researchers modeled how the variant might affect protein function, but its clinical significance remained uncertain and it was not treated as a confirmed cause. At the latest follow-up, she was alive, asymptomatic, and disease-free while attending annual biochemical, hematologic, and imaging surveillance. She valued the effort her clinicians made to investigate her family history and possible inherited risk, while recognizing that the FANCA finding was not definitive.